Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Coya Therapeutics, Inc.NASDAQ: COYA
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $3.9M, compared with -$2.81M a year earlier. Trailing-twelve-month net change in cash was $15.19M. Over 3 fiscal years it compounded at +74.6% a year.
Context
- Net change in cash amounted to 106.8% of revenue in FY2025, down 54.0 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $3.9M or moves back toward the trailing-twelve-month quarterly average of $3.8M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 8.48M USD
- Year-over-year change
- +48.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.48M | +48.5% |
| FY2024 | 2024-12-31 | 5.71M | -78.6% |
| FY2023 | 2023-12-31 | 26.69M | +1575.1% |
| FY2022 | 2022-12-31 | 1.59M | +136.4% |
| FY2021 | 2021-12-31 | (4.38M) | — |
Net Change in Cash vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 net change in cash of $15.19M is the 8th largest of the 11 companies compared; the peer median is $6.95M.
- Its year-over-year change of +3411.8% is the highest of 11, against a peer median of +29.3%.
- Net change in cash amounts to 191.4% of revenue for COYA, versus a peer median of 1024.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $79.05M | -221.2% | +105.0% | 50.3% | |
| LTM Mar 2026 | $72.93M | +856.8% | -54.9% | 1024.0% | |
| LTM Mar 2026 | $69.75M | +211.9% | +12.7% | — | |
| LTM Mar 2026 | $63.33M | +572.7% | — | — | |
| LTM Mar 2026 | $61.31M | -209.6% | -38.7% | — | |
| LTM Mar 2026 | $34.82M | -143.9% | +26.2% | — | |
| LTM Mar 2026 | $29.52M | +295.4% | -58.6% | 2952.1% | |
| LTM Mar 2026 | $15.19M | +3411.8% | +74.6% | 191.4% | |
| LTM Mar 2026 | $10M | -331.8% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $8.83M | +125.8% | — | 123.6% |
| LTM Mar 2026 | $3.89M | -67.3% | -39.8% | 2905.2% | |
| Peer median (excluding COYA) | $6.95M | +29.3% | -38.7% | 1024.0% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.